Status:
COMPLETED
LGBTQ-affirmative CBT for Youth
Lead Sponsor:
Yale University
Conditions:
Anxiety Disorders
Depression
Eligibility:
All Genders
12-17 years
Phase:
NA
Brief Summary
This study will adapt LGBTQ-affirmative cognitive behavior therapy (CBT) - previously only used with adults - for youth aged 12-17 years. This intervention addresses the pathways through which minorit...
Detailed Description
Lesbian, gay, bisexual, transgender, and queer (LGBTQ) youth experience more mental health problems than their heterosexual and cisgender peers. The purpose of the proposed mixed-methods study is to a...
Eligibility Criteria
Inclusion
- 12-17 years old
- Self-identify as LGBTQ (any diverse sexual orientation and/or gender identity)
- Live in New York, New Jersey, or Connecticut
- Fluent in English
- Meet diagnostic criteria for a DSM-5 internalizing disorder (any depressive, anxiety, obsessive-compulsive, or adjustment disorder)
- Have consistent, weekly access to an Internet-enabled electronic device that allows for video-conferencing
- Availability to attend 10 weekly 90 minute intervention sessions in summer 2021
- Access to a quiet, private place for intervention sessions
- Provision of informed consent from parent/guardian and assent from the youth
Exclusion
- Evidence of any psychotic or bipolar spectrum diagnosis
- Active suicidality and/or homicidality (defined as active intent or concrete plan, as opposed to passive ideation) or psychiatric hospitalization within the past 6 months
- Significant cognitive impairment (as determined by an intellectual disability screener) or significant developmental disorder (if impairing youth's ability to participate in group therapy)
- Significant behavior disorder (e.g., oppositional defiant disorder, conduct disorder) if impairing youth's ability to participate in group therapy
- Currently in mental health treatment exceeding one day per month
- Received any cognitive-behavioral therapy treatment in the past 12 months
- Unstable psychotropic medications (defined as changes to antidepressant dosage in the past 3 months, or changes to a benzodiazepine dosage in the past month)
Key Trial Info
Start Date :
August 31 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 26 2022
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT05408858
Start Date
August 31 2021
End Date
January 26 2022
Last Update
May 31 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. Pachankis' Lab
New York, New York, United States, 10010